Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

Celgene has had a difficult few months, with the latest knock coming after its blood cancer blockbuster Revlimid (lenalidomide) failed to hit the mark in non-Hodgkin’s lymphoma, the failure ... of Crohn’s disease candidate GED-0301, and lacklustre

Latest news

  • CAR-T therapies show long-term benefits in lymphoma CAR-T therapies show long-term benefits in lymphoma

    CAR-T therapies show long-term benefits in lymphoma. Novartis’Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients. ... One-year results from the ZUMA-1 trial of Gilead’s Yescarta (axicabtagene ciloleucel)

  • AZ gets early FDA green light for Imbruvica challenger AZ gets early FDA green light for Imbruvica challenger

    AstraZeneca claimed its first regulatory approval for BTK inhibitor acalabrutinib in the US, with the FDA clearing the drug for second-line therapy for adults with mantel cell lymphoma. ... According to the FDA, MCL is a rare and fast-growing type of

  • Novartis moves swiftly with lymphoma filing for CAR-T Kymriah Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

    Novartis moves swiftly with lymphoma filing for CAR-T Kymriah. Will go up against Kite Pharma's Yescarta if approved. ... Now, Novartis wants to extend its use into relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common forms of non

  • AbbVie and Roche plan Venclexta combo filings in leukaemia AbbVie and Roche plan Venclexta combo filings in leukaemia

    AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... 8bn last year in CLL, mantle cell lymphoma (MCL), Waldenström

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Aliqopa (copanlisib) has been given a conditional green light as a third-line treatment for patients with relapsed

More from news
Approximately 15 fully matching, plus 107 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Quick links

Infographics

Multimedia